No Data
Broge Pharmaceuticals: 2024 Annual Report
Broge Pharmaceuticals: 2024 Annual Report Summary
Boji Pharmaceuticals: Report for the first quarter of 2025
Boji Medical Technology (300404.SZ): In the first quarter, the net income was 3.9006 million yuan, a year-on-year decrease of 76.38%.
On April 25, Gelonghui reported that Boji Medical Technology (300404.SZ) published its Q1 2025 report, achieving revenue of 0.139 billion yuan, a year-on-year decrease of 17.06%; net income attributable to shareholders of the listed company was 3.9006 million yuan, a year-on-year decrease of 76.38%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.6979 million yuan, a year-on-year decrease of 88.28%; basic EPS was 0.0102 yuan.
Boji Medical Technology Co.,Ltd.'s (SZSE:300404) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Boji Medical Technology (300404.SZ): The impact of the USA's current tariff policy on the company's operation is extremely limited.
On April 7, Global Creative reported that Boji Medical Technology (300404.SZ) stated on the investor interaction platform that the company's overseas business accounts for less than 1%, and the impact of the current tariff policy in the USA on the company's operation is extremely limited.
Market Cool On Boji Medical Technology Co., Ltd.'s (SZSE:300404) Revenues Pushing Shares 25% Lower
